JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB121472

Anti-LRIG2 antibody

Be the first to review this product! Submit a review

|

(2 Publications)

Rabbit Polyclonal LRIG2 antibody. Suitable for IHC-P, ICC/IF and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human LRIG2 aa 850-1050.

View Alternative Names

KIAA0806, LIG2, LRIG2, Leucine-rich repeats and immunoglobulin-like domains protein 2, LIG-2

3 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRIG2 antibody (AB121472)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRIG2 antibody (AB121472)

ab121472 at 1/10 dilution staining LRIG2 in Human skeletal muscle tissue by Immunohistochemistry.

Immunocytochemistry/ Immunofluorescence - Anti-LRIG2 antibody (AB121472)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-LRIG2 antibody (AB121472)

ab121472 at 2 μg/ml staining LRIG2 in human cell line A-43 tissue by Immunocytochemistry/Immunofluorescence

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRIG2 antibody (AB121472)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRIG2 antibody (AB121472)

ab121472 at 1/10 dilution staining LRIG2 in Human epididymis tissue by Immunohistochemistry.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

ICC/IF, IHC-P

applications

Immunogen

Recombinant Fragment Protein within Human LRIG2 aa 850-1050. The exact immunogen used to generate this antibody is proprietary information.

O94898

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/20 - 1/50", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "0.2-0.25 µg/mL", "ICCIF-species-notes": "<p></p>" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.2 Preservative: 0.02% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

See full target information LRIG2
style
left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Journal for immunotherapy of cancer 10: PubMed36096529

2022

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization.

Applications

Unspecified application

Species

Unspecified reactive species

Jinyang Hu,Feng Dong,You He,Xianyou Xia,Fangling Cheng,Sui Chen,Xiaoshuang Hou,Po Zhang,Guohao Liu,Ying Li,Qian Gao,Minhai Dong,Ting Li,Wei Li,Qungen Xiao,Xiaopeng Li,Xingjiang Yu,Guifa Xi,Dongsheng Guo,Xudong Wu,Baofeng Wang

Oncogenesis 7:3 PubMed29358688

2018

LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle.

Applications

Unspecified application

Species

Unspecified reactive species

Dae-Shik Suh,Si Eun Park,Hanyong Jin,Kangseok Lee,Jeehyeon Bae
View all publications
style
left-column
style
left-column
style
right-column

Alternative Products

Primary Antibodies

AB157492

Anti-LRIG2 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRIG2 antibody (AB157492)

  • 0
  • 0

Complementary Products

Primary Antibodies

AB55407

Anti-KRT81 antibody [3B10-5B10]

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-KRT81 antibody [3B10-5B10] (AB55407)

  • 0
  • 0
Primary Antibodies

AB283263

Anti-TPOR/MPL antibody [EPR24566-47]

20ul selling size|RabMAb|Recombinant|Trial Size

Flow Cytometry - Anti-TPOR/MPL antibody [EPR24566-47] (AB283263)

  • 0
  • 0
Primary Antibodies

AB121173

Anti-ZNF589 antibody

Immunocytochemistry/ Immunofluorescence - Anti-ZNF589 antibody (AB121173)

  • 0
  • 0
Primary Antibodies

AB121146

Anti-TAGLN2 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TAGLN2 antibody (AB121146)

  • 5
  • 1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com